• Explore /
  • Poster
  • / Enfortumab vedotin (EV) as monotherapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results of stage I of a phase 2 trial.

Enfortumab vedotin (EV) as monotherapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results of stage I of a phase 2 trial.

Abstract Poster

Authors

null

Umang Swami

Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT

Umang Swami , Benjamin L. Maughan , Kenneth M. Boucher , Blake Nordblad , Jennifer Lloyd , Julia Batten , Tenzin Kunsang Phunrab , Joshua Quertinmont , Manish Kohli , Sumati Gupta , Neeraj Agarwal

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04754191

Citation

J Clin Oncol 42, 2024 (suppl 4; abstr 152)

DOI

10.1200/JCO.2024.42.4_suppl.152

Abstract #

152

Poster Bd #

G2

Abstract Disclosures

Similar Posters

First Author: Johann S. De Bono

First Author: Daniel Peter Petrylak

First Author: Daniel Peter Petrylak

First Author: Ronan Flippot